IN8bio Statistics

Total Valuation

IN8bio has a market cap or net worth of $13.25 million. The enterprise value is $5.63 million.

Market Cap	13.25M
Enterprise Value	5.63M

Important Dates

The last earnings date was Wednesday, May 7, 2025, after market close.

Earnings Date	May 7, 2025
Ex-Dividend Date	n/a

Share Statistics

IN8bio has 81.26 million shares outstanding. The number of shares has increased by 84.32% in one year.

Current Share Class	81.26M
Shares Outstanding	81.26M
Shares Change (YoY)	+84.32%
Shares Change (QoQ)	+8.25%
Owned by Insiders (%)	6.46%
Owned by Institutions (%)	15.73%
Float	60.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.95
P/TBV Ratio	0.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.30, with a Debt / Equity ratio of 0.31.

Current Ratio	4.30
Quick Ratio	4.02
Debt / Equity	0.31
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -174.66% and return on invested capital (ROIC) is -80.38%.

Return on Equity (ROE)	-174.66%
Return on Assets (ROA)	-73.25%
Return on Invested Capital (ROIC)	-80.38%
Return on Capital Employed (ROCE)	-157.37%
Revenue Per Employee	n/a
Profits Per Employee	-$1.52M
Employee Count	18
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -83.86% in the last 52 weeks. The beta is 0.23, so IN8bio's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	-83.86%
50-Day Moving Average	0.19
200-Day Moving Average	0.32
Relative Strength Index (RSI)	41.68
Average Volume (20 Days)	651,290

Short Selling Information

The latest short interest is 426,329, so 0.52% of the outstanding shares have been sold short.

Short Interest	426,329
Short Previous Month	478,257
Short % of Shares Out	0.52%
Short % of Float	0.70%
Short Ratio (days to cover)	0.57

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-26.61M
Pretax Income	-31.96M
Net Income	-27.43M
EBITDA	-24.73M
EBIT	-26.61M
Earnings Per Share (EPS)	-$0.43

Full Income Statement

Balance Sheet

The company has $11.89 million in cash and $4.27 million in debt, giving a net cash position of $7.62 million or $0.09 per share.

Cash & Cash Equivalents	11.89M
Total Debt	4.27M
Net Cash	7.62M
Net Cash Per Share	$0.09
Equity (Book Value)	13.88M
Book Value Per Share	0.17
Working Capital	9.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$19.35 million and capital expenditures -$116,000, giving a free cash flow of -$19.47 million.

Operating Cash Flow	-19.35M
Capital Expenditures	-116,000
Free Cash Flow	-19.47M
FCF Per Share	-$0.24

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IN8bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-84.32%
Shareholder Yield	-84.32%
Earnings Yield	-207.06%
FCF Yield	-146.98%

Analyst Forecast

The average price target for IN8bio is $3.60, which is 2,108.59% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.60
Price Target Difference	2,108.59%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2